Olmesartan Medoxomil Accord (Olmesartan Medoxomil)

Olmesartan Medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes.
• Heart failure: used as part of combination therapy to improve symptoms and outcomes.

• Olmesartan medoxil is a pro‑drug that is rapidly converted to olmesartan, a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1 receptors, it prevents angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sympathetic activation, leading to vasodilation, reduced sodium‑water retention, and lower systemic blood pressure.

Olmesartan Medoxil Accord may cause a range of adverse reactions.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea
• Cough

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Liver enzyme elevations
• Allergic skin reactions such as Stevens‑Johnson syndrome

When prescribing Olmesartan Medoxil Accord, clinicians should consider several safety aspects.

• Monitor blood pressure: ensure adequate control without excessive lowering.
• Assess renal function: check serum creatinine and eGFR before initiation and periodically.
• Check electrolytes: especially potassium levels, to avoid hyper‑kalaemia.
• Avoid in pregnancy: drug is contraindicated in the second and third trimesters.
• Use cautiously in hepatic ​  
• Store at ambient temperature: keep  
• Keep  

-  

• Olmes-
• ---
•   
•